Visfatin is related to lipid dysregulation, endothelial dysfunction and atherosclerosis in patients with chronic kidney disease.

Conclusion: Overall, the study showed that in CKD patients, higher visfatin levels are associated with decreased GFR, increased serum triglyceride and LDL cholesterol levels and impaired endothelial function. Moreover, visfatin levels also correlated with hsCRP levels and carotid IMT, suggesting that visfatin may play an important role in uremia-related atherosclerosis.
PMID: 20602330 [PubMed - as supplied by publisher] (Source: Journal of Nephrology)